

Appl. No.: 09/973,375
Amdt. dated 02/01/2005
Reply to Office action of November 4, 2004

Amendments to the Claims

1. (Currently amended) A method of treating a traumatic central nervous system injury, said method comprising administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a composition comprising allopregnanolone.
2. (Originally filed) The method of claim 1, wherein said injury is a traumatic brain injury.
3. (Originally filed) The method of claim 2, wherein said traumatic brain injury results from a blunt force contusion.
4. (Originally filed) The method of claim 1, wherein said method reduces edema in the patient following said traumatic CNS injury.
5. (Originally filed) The method of claim 1, wherein said method reduces the inflammatory response in the patient following said traumatic CNS injury.
6. (Originally filed) The method of claim 1, wherein said method reduces neuronal cell death in the patient following said traumatic CNS injury.
7. (Originally filed) The method of claim 1, wherein said allopregnanolone is administered in at least one dosage of about 1 µg/kg to about 50 mg/kg of body weight.
8. (Originally filed) The method of claim 7, wherein said allopregnanolone is administered in at least one dosage of about 4 mg/kg of body weight.

Appl. No.: 09/973,375
Amdt. dated 02/01/2005
Reply to Office action of November 4, 2004

9. (Originally filed) The method of claim 7, wherein at least one dosage of said allopregnanolone is administered about 0.5 to about 100 hours following the traumatic CNS injury.

10. (Originally filed) The method of claim 7, wherein the first dose of the allopregnanolone is administered about 1 hour following the traumatic CNS injury, and a subsequent allopregnanolone dose is administered about 6 hours following the injury.

11. (Originally filed) The method of claim 7, wherein the first dose of the allopregnanolone is administered about 1 hour following the traumatic brain injury, a second allopregnanolone dosage is administered about 6 hours following the injury, and subsequent allopregnanolone dosages are administered in 24 hour intervals.

12. (Originally filed) The method of claim 1, wherein said allopregnanolone is administered by intraperitoneal, subcutaneous, intravenous or intracerebroventricular administration or any combination thereof.

13. (Canceled)

14. (Currently amended) The method of claim 143, wherein said pharmaceutical composition comprises a carrier comprising cyclodextrin.

15. (Originally filed) The method of claim 1, wherein said composition further comprises at least one other neurotrophic agent.

16. (Currently amended) A method of decreasing neurodegeneration on a population of cells in a patient subject following a traumatic injury to the central nervous system, said method comprising administering to the a patient in need thereof a pharmaceutical composition

Appl. No.: 09/973,375
Amdt. dated 02/01/2005
Reply to Office action of November 4, 2004

comprising a therapeutically effective dose of allopregnanolone, wherein said dose produces a neuroprotective effect in the patient.

17. (Originally filed) The method of claim 16, wherein said traumatic CNS injury is a traumatic brain injury.

18. (Originally filed) The method of claim 17, wherein the neurodegeneration is associated with cerebral edema.

19. (Originally filed) The method of claim 17, wherein the neurodegeneration is associated with a blunt force contusion.

20. (Originally filed) The method of claim 17, wherein the neurodegeneration is associated with an inflammatory response.